Alexis Denmon Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 370 Chamberlain Ave Apt 3, Paterson, NJ 07502 Phone: 908-868-5369 |
Miss Jenniffer Lorena Castro Castro Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 940 E 25th St, Paterson, NJ 07513 Phone: 973-341-6393 |
Ariana Geiger, MSOT, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 97 Spruce St, Paterson, NJ 07501 Phone: 973-860-3268 |
Jessica Erin Dzioba, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 703 Main St, Paterson, NJ 07503 Phone: 973-754-4308 |
Indu Sharma, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 186 6th Ave Fl 1, Paterson, NJ 07524 Phone: 201-655-3207 |
Radiology And Rehab Pa Llc Occupational Therapist Medicare: Medicare Enrolled Practice Location: 185 6th Ave, Paterson, NJ 07524 Phone: 201-655-3207 |
News Archive
Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announces the creation of Salix Pharmaceuticals' Hepatic Encephalopathy Living Program. H.E.L.P. launched May 24, 2010, and coincides with the launch of Xifaxan550 (rifaximin) for the management of patients 18 or older at risk for overt hepatic encephalopathy recurrence.
Tinnitus, migraine, epilepsy, depression, schizophrenia, Alzheimer's: all these are examples of diseases with neurological causes, the treatment and study of which is more and more frequently being carried out by means of magnetic stimulation of the brain. However, the method's precise mechanisms of action have not, as yet, been fully understood.
Don't procrastinate. Most consumers who buy their own insurance on the federal health insurance marketplace face a Dec. 15 deadline. Advocates are reminding these customers that if they miss the deadline, they may not have a plan that starts in January 2019.
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
› Verified 9 days ago